Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. (Q39507883)

PubMed publication ID

21750471

12 September 2017

title

Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

author name string

Kathryn Kelly Erickson-Ridout

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

Junjia Zhu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

Philip Lazarus

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

publication date

1 September 2011

1 reference

PubMed publication ID

21750471

Pharmacogenetics and Genomics

12 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

page(s)

539-551

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

describes a project that uses

13 May 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6281394/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Antipsychotics and the risk of diabetes: a general data review

1 reference

12 December 2020

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response

1 reference

12 December 2020

Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans

1 reference

12 December 2020

Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.

1 reference

12 December 2020

The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases

1 reference

12 December 2020

Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4

1 reference

12 December 2020

Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes

1 reference

12 December 2020

Olanzapine versus other atypical antipsychotics for schizophrenia

1 reference

12 December 2020

Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes

1 reference

12 December 2020

Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites

1 reference

12 December 2020

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

1 reference

12 December 2020

UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism

1 reference

12 December 2020

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

1 reference

12 December 2020

Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?

1 reference

12 December 2020

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

1 reference

12 December 2020

Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform

1 reference

12 December 2020

Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.

1 reference

12 December 2020

Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention

1 reference

12 December 2020

Novel antipsychotics: comparison of weight gain liabilities.

1 reference

12 December 2020

Management of schizophrenia with obesity, metabolic, and endocrinological disorders

1 reference

12 December 2020

Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype

1 reference

12 December 2020

Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors

1 reference

12 December 2020

The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers

1 reference

12 December 2020

Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients

1 reference

12 December 2020

Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

1 reference

12 December 2020

Weight effects associated with antipsychotics: a comprehensive database analysis

1 reference

12 December 2020

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

1 reference

12 December 2020

Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10.

1 reference

12 December 2020

Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen

1 reference

12 December 2020

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

1 reference

12 December 2020

The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

12 December 2020

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients

1 reference

12 December 2020

Glucuronidation of tobacco-specific nitrosamines by UGT2B10

1 reference

12 December 2020

O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

1 reference

12 December 2020

Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms

1 reference

12 December 2020

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid.

1 reference

12 December 2020

The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).

1 reference

12 December 2020

Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents

1 reference

12 December 2020

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

1 reference

12 December 2020

Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines

1 reference

12 December 2020

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

12 December 2020

Disposition and biotransformation of the antipsychotic agent olanzapine in humans

1 reference

12 December 2020

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

12 December 2020

Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.

1 reference

12 December 2020

In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction

1 reference

12 December 2020

10.1097/FPC.0B013E328348C76B

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6281394&resulttype=core&format=json

13 May 2020

PubMed publication ID

21750471

1 reference